Delphi Ventures

Arrow Markets operates a decentralized financial market options protocol designed to democratize returns for option market makers. The company’s platform eliminates intermediaries in the traditional options trading process, including brokers and clearinghouses, thereby passing the resulting savings directly to users. By offering cash-settled options and streamlining the entire trading pipeline—from market making to clearing and settlement—Arrow Markets enables liquidity providers to mimic the hedging activities typically associated with traditional market makers. This innovative approach aims to enhance accessibility and efficiency within the options trading landscape.

MyShell is a decentralized platform focused on enabling the discovery, creation, and staking of AI-native applications. The company provides tools that leverage advanced generative AI models, allowing creators to transform their ideas into functional applications. By fostering an ecosystem where creators can not only develop their models but also make them widely accessible, MyShell supports the transition of individuals into contributors within the field of artificial intelligence, enhancing collaboration and innovation within the sector.

Chainway Labs is a blockchain infrastructure company specializing in Bitcoin, Ethereum, and Zero Knowledge technology. Its flagship project, Citrea, is the first ZK Rollup on Bitcoin, aiming to enhance Bitcoin's transaction capabilities and facilitate the development of decentralized applications, including DeFi and NFTs, on the Bitcoin network.

Nous Research specializes in developing human-centric artificial intelligence models. Their focus is on creating flexible and adaptable AI systems that enhance reasoning and align with practical user experiences. They achieve this by employing open-source development, advanced language architecture, data synthesis, and fine-tuning techniques.

Hytopia is a metaverse platform that focuses on creating a social and interactive environment through voxel-based gaming. By offering a game creation toolkit inspired by Minecraft, Hytopia empowers developers to design engaging games while incorporating flexible monetization options. The platform aims to connect users through social gaming experiences, allowing them to explore diverse metaverse worlds and forge new friendships. Hytopia fosters a transparent and open monetization layer, enhancing the accessibility and enjoyment of various games and communities within the metaverse.

FastLane is a developer of a platform aimed at enhancing network efficiency and user experience in the blockchain space. The protocol focuses on generating revenue for validators while optimizing the performance of algorithmic traders. It employs ecosystem-friendly MEV relays to minimize transaction spam and bolster network health. This approach not only safeguards user interactions but also boosts the yield of liquid staking derivatives, improving the chances of success for beneficial trading bots. By simplifying the integration of sentry nodes through a single command line, FastLane aims to streamline operations for users and contribute to a more effective and sustainable blockchain environment.

Karate Combat is a professional organization dedicated to revitalizing the martial art of karate through a series of full-contact events and tournaments. The company organizes leagues that feature fighters competing under specific rules designed to promote continuous action, enhancing the viewing experience. These events take place in diverse and exotic locations worldwide, showcasing high-quality production comparable to Hollywood standards. In addition to hosting competitions, Karate Combat also provides training opportunities and sells tickets for its events, aiming to engage both fighters and fans in the dynamic world of karate.

Mirage is focused on developing an augmented reality infrastructure and artist tooling platform aimed at enhancing digital art and media services. The company creates tools that enable digital artists to easily create, distribute, and store augmented reality content. This platform facilitates the engagement of creators and audiences, allowing them to build and curate a decentralized trans-digital reality that seamlessly connects the physical and digital realms. Through its innovative approach, Mirage aims to empower artists and enhance the overall experience of digital art.

Skylock, established in 2022 in Ottawa, Canada, is a post-seed startup specializing in real-time security for decentralized finance (DeFi) protocols. It proactively defends against smart-contract hacks by detecting and blocking malicious transactions, safeguarding assets, and ensuring their safe return to users. Skylock's cutting-edge technology aims to enhance the stability and security of the DeFi industry.

Godmode is the AI-native sales enablement tools. Helps you connect and build with genuine human relationships and proactively finds you leads based on your ideal customer profile and signals on the web.

Suberra is a company focused on facilitating cryptocurrency transactions for businesses by providing an innovative payment infrastructure. It enables merchants to accept crypto payments, including one-time payments and subscriptions, in a safe and secure manner. By offering a recurring payment protocol, Suberra enhances the user experience for both consumers and sellers, allowing for seamless financial transactions using cryptocurrencies and stablecoins. The company's solutions are designed to simplify the payment process, making it easier for businesses to integrate crypto payments into their commerce strategies while ensuring that users can transact freely and efficiently.

Jito Labs is a blockchain infrastructure company focused on enhancing the Solana network through the development of systems that maximize miner extraction value (MEV) while mitigating its adverse effects. The company provides an open-source, third-party validator specifically designed for the Solana blockchain, facilitating the creation of efficient and profitable blocks. Jito Labs aims to enable users to increase their revenue and optimize hardware utilization through its innovative validator client. By prioritizing both network scalability and validator rewards, Jito Labs plays a critical role in advancing the capabilities and profitability of the Solana ecosystem.

AMGI Studios is an animation technology agency that specializes in real-time animation, art direction, and puppeteering, integrating these services into existing studio pipelines. The company focuses on the intersection of animation and gaming, developing and producing both traditional entertainment and Web3 native properties. By utilizing proprietary technology and innovations in real-time animation, AMGI Studios enables animators to create animated art that merges artistry with cutting-edge technology. Their offerings cater to a diverse landscape of animated content and animation technology services, positioning them as a significant player in the evolving animation industry.

Tatsumeeko is a Discord-first fantasy massively multiplayer online role-playing game (MMORPG).

ZGEN is a software firm that builds smart contracts on web3 applications for DeFi and DAO communities. They also involve in tobBuilding essentials for internet communities.

Voyage Finance is a developer of a Web3 game-based loan platform that caters to gamers and gaming guilds. The company specializes in providing decentralized loans tailored for the gaming community, offering a range of financial services designed to enhance the gaming experience. Its platform facilitates various features, including the purchase of yield-generating assets and a "play and repay" option for loans, ensuring that users can access financial support while engaging in their gaming activities. By focusing on the unique financial needs of gamers and guilds, Voyage Finance aims to create a convenient and supportive environment for the growing intersection of finance and gaming.

Pollen Mobile operates a decentralized mobile network powered by blockchain technology. It enables users to own and operate the network, offering reliable and affordable connectivity with a focus on user privacy.

Polemos is a global gaming company that provides information, education, and asset management solutions to the strategy gaming industry. Founded in 2020 by a team of international co-founders with expertise in gaming, finance, and technology, Polemos offers proprietary asset management solutions, non-collateralized lending, learning management systems, and advanced game/player data analytics. Led by CEO Richard McLaren, a renowned technology executive, and Hal Crawford, former Chief Editor and Publisher at Microsoft NineMSN, the company is expanding into global markets. Polemos' co-founders include gaming industry pioneers such as Tom Hall, former CEO of Playtech and Asian Logic, and Zac Rosenberg, Managing Partner at Capzed. The company aims to leverage the experience of sophisticated gamers, offering technical and competitive games on the blockchain, enabling players to play and earn with non-fungible token games.

Crypto Raiders is a highly-interactive dungeon crawler game built on the blockchain. Players have the ability to buy characters and mobs, go on missions, build teams in a virtual universe all while discovering NFTs they then own. Crypto Raiders is built on the Polygon blockchain, and all NFT loot is randomized, ensuring that the value of all discovered loot is random as well.

Crypto Unicorns is a Web3 game development and research and development studio.

MetalCore is a maker of computer games. They provide services for fighting games. They provide products that include mechs, infantry, aircraft, and vehicles.

Squads is a developer of a decentralized program that enables the establishment of better and easier decentralized autonomous groups. The company's application combines all of the key components of a decentralized autonomous organization, such as deployment, treasury, vault management, on-chain voting, and chat, into a single portal with an easy-to-use interface, allowing users to streamline daily operations using a decentralized autonomous organization structure.

Jambo is a technology company building an on-chain mobile network driven by the JamboPhone, a crypto-native smartphone and ecosystem that combines hardware, software, and decentralized services. It operates a distributed mobile-network foundation with nodes across many countries to enable decentralized use cases such as validators and peer-to-peer networking while reducing connectivity costs. The platform includes the JamboApp, which features a multi-chain wallet, an ecosystem dApp store, and opportunities to earn rewards. It also supports gaming smartphones with integrated blockchain technology and financial software to connect users with the global on-chain economy. Jambo aims to onboard millions into the on-chain economy by enabling access to games, cryptocurrency trading, and decentralized finance, with the Jambo Token powering rewards and ecosystem incentives.

EnterDAO is a decentralized autonomous organization developing products to facilitate new markets within the Web3 metaverse economy. It offers a cross-platform web3-enabled desktop application serving as a single entry point for users to access and interact with various simulated reality games and virtual lands.

DOOMSDAYX is a creative technology studio dedicated to supporting web3 artists and their fans, with an emphasis on transforming culture through on-chain innovations. The studio specializes in educating artists about non-fungible tokens (NFTs) and the broader web3 ecosystem. By offering a range of services, DOOMSDAYX empowers artists to connect with the native crypto community and reach a wider retail audience. Additionally, the company fosters deeper engagement between fans and their favorite artists, enhancing the overall experience within the web3 landscape.

Hubble Protocol is a decentralized financial platform that facilitates long-term borrowing, lending, and the creation of structured financial products. It aims to democratize access to decentralized finance by offering a range of sustainable financial services. The protocol's software supports multi-asset collateral and enables zero-interest borrowing, allowing users to leverage yield-bearing assets for loans. Additionally, Hubble enhances yield generation on deposits of various tokens, providing clients with optimized financial opportunities while minimizing costs associated with loans.

Friktion Labs is a decentralized finance (DeFi) company focused on portfolio management, equipped with a team of quantitative traders, researchers, and crypto engineers experienced in commodities, treasuries, and crypto-assets. The organization has assembled a team of derivatives traders and market makers with expertise from notable firms in the trading sector. Friktion offers an automated portfolio manager (APM) that allows users to input their existing portfolio details, including spot trading, perpetual contracts, and liquidity positions. This platform is designed to help investors maximize profits and monitor fluctuations across various market cycles, promoting sustainable and informed investing practices.

Suberra is a company focused on facilitating cryptocurrency transactions for businesses by providing an innovative payment infrastructure. It enables merchants to accept crypto payments, including one-time payments and subscriptions, in a safe and secure manner. By offering a recurring payment protocol, Suberra enhances the user experience for both consumers and sellers, allowing for seamless financial transactions using cryptocurrencies and stablecoins. The company's solutions are designed to simplify the payment process, making it easier for businesses to integrate crypto payments into their commerce strategies while ensuring that users can transact freely and efficiently.

Hubble Protocol is a decentralized financial platform that facilitates long-term borrowing, lending, and the creation of structured financial products. It aims to democratize access to decentralized finance by offering a range of sustainable financial services. The protocol's software supports multi-asset collateral and enables zero-interest borrowing, allowing users to leverage yield-bearing assets for loans. Additionally, Hubble enhances yield generation on deposits of various tokens, providing clients with optimized financial opportunities while minimizing costs associated with loans.

Beta Finance is a decentralized finance protocol specializing in lending, borrowing, and short-selling of crypto assets. It aims to mitigate crypto volatility and promote market stability through its user-friendly platform, enabling traders of all skill levels to manage their short positions effectively.

LayerZero develops a blockchain interoperability platform that enables data exchange between disparate blockchains. Its platform achieves speed and security by validating as an on-chain light node, allowing companies to build cross-chain applications using a low-level communication primitive.

Tessera's mission is to curate the most extraordinary collective ownership experiences produced by the greatest creators, builders, and leaders. Tessera's vision is a world where anyone can have the opportunity to collectively own and govern things they value, without reliance on central gatekeepers to execute decisions and actions on their behalf.

Pontem Network is a product studio focused on developing foundational decentralized applications (dApps) for the Aptos blockchain. Its flagship product, the Pontem Wallet, is a secure wallet available on multiple platforms, including Chrome, Firefox, iOS, and Android, allowing users to store and send tokens on the Aptos network. The wallet is integrated with various services, including the Liquidswap decentralized exchange, NFT marketplaces like Topaz and Souffl3, and liquid staking platforms such as Ditto and Tortuga. Additionally, Pontem Network offers tools for developers, including the Move Playground browser code editor, the Move IntelliJ IDE plugin, and ByteBabel, a Solidity-to-Move code translator that enables Ethereum Virtual Machine compatibility on Aptos. Through these products, Pontem Network aims to facilitate innovation and support the growth of the Aptos ecosystem.

Bright Star Studios is an independent global game development studio based in Swatar, Malta. The company specializes in creating multiplayer online video games compatible with mobile devices, personal computers, and browsers. Their flagship title is Ember Sword, a free-to-play fantasy MMORPG offering competitive gameplay across platforms.

Fractal is a financial technology company that provides digital assets and blockchain adoption services. They also develop tools for institutional investors to access decentralized financing.

Fully permissionless protocol for decentralized perpetual swaps

Covalent Research & Development Inc. is a technology company based in Vancouver, Canada, focused on enhancing transparency and accountability in the cryptocurrency sector. Established in 2018, Covalent develops a data analytics suite that addresses significant infrastructure challenges obstructing blockchain adoption. Its offerings include on-chain data and analytics for the Ethereum network, as well as APIs that provide visibility and transparency across various blockchain networks. The company aims to bridge centralized databases with decentralized blockchain technologies, thereby facilitating adoption among enterprises and consumers. Covalent supports several leading decentralized finance protocols and is actively building tools like SafeKeeep, which aims to improve data availability and record-keeping in the DeFi space. The company’s team comprises industry veterans with extensive experience in database and distributed systems, underscoring its commitment to driving innovation in blockchain technology.

XDefi Wallet is a decentralized, non-custodial cryptocurrency wallet designed to enable users to securely store, send, and swap digital assets across multiple blockchains. It supports over 30 different blockchains, providing a versatile platform for managing a wide range of cryptocurrencies and NFTs. The wallet is engineered to facilitate interactions with various decentralized finance (DeFi) protocols, enhancing user engagement in the growing DeFi ecosystem. With features that allow access to NFT marketplaces and applications, XDefi Wallet empowers users to visualize and manage their collectibles effectively. By prioritizing security and user-friendliness, XDefi Wallet has garnered a user base of over 200,000 individuals, establishing itself as a trusted solution for those seeking to navigate the complexities of digital asset management.

Anchor Protocol is a savings platform that provides crypto natives, fintech companies, and investors a stable, high interest rate finance. The company was founded in 2020 and is headquartered in Seoul, South Korea.

RECUR designs & develops on-chain branded experiences for fans to buy, collect, and re-sell NFTs. RECUR is chain agnostic and is fundamentally changing the NFT market by creating and setting the standard for a decentralized recurring royalty, creating the widest distribution and reach for NFTs minted on their platform. It was founded in 2021 and headquartered in Miami, Florida.

Armor develops a dynamic cover brokerage protocol for decentralized finance to serve cryptocurrency investors. Founded in 2021, Armor is a DeFi coverage aggregator that makes securing your DeFi assets against hacks as easy as possible. Ease wants to make DeFi as easy and safe as possible. They aim to cover every dollar in DeFi so that users can finally feel at ease.

Caravan Wellness specializes in delivering corporate wellness programs and online education solutions aimed at enhancing individual health and productivity. The company offers a range of wellness lessons, programs, and challenges led by experts, focusing on nutrition, fitness, mindfulness, and overall well-being. By utilizing scientific principles and data optimization, Caravan Wellness empowers individuals to adopt healthier habits and achieve peak performance in their daily lives. In addition to its educational content, the company engages in social media campaigns and establishes brand partnerships to amplify its impact and reach. Through these initiatives, Caravan Wellness provides comprehensive support for promoting employee wellness and fostering a culture of health within organizations.

LeddarTech develops advanced detection and ranging systems using infrared LEDs and algorithms. It offers off-the-shelf smart sensor modules for various applications such as traffic management, autonomous vehicles, smart homes, and agriculture. The company provides interconnected sensor solutions for infrastructure, pollution monitoring, mobility, and traffic management in cities.

AEGEA Medical, Inc. is a medical technology company based in Menlo Park, California, that specializes in innovative treatments for women's health. The company has developed a water vapor ablation system, known as Mara, which is designed for the in-office treatment of heavy menstrual bleeding, specifically menorrhagia. This FDA-approved technology utilizes adaptive vapor ablation to deliver safe and effective endometrial ablation in a simple procedure that takes only minutes. AEGEA Medical aims to expand treatment options for a broader range of patients while ensuring convenience and confidence for physicians performing these office-based procedures. The company was incorporated in 2007 and continues to focus on enhancing patient outcomes in women's healthcare.

AEGEA Medical, Inc. is a medical technology company based in Menlo Park, California, that specializes in innovative treatments for women's health. The company has developed a water vapor ablation system, known as Mara, which is designed for the in-office treatment of heavy menstrual bleeding, specifically menorrhagia. This FDA-approved technology utilizes adaptive vapor ablation to deliver safe and effective endometrial ablation in a simple procedure that takes only minutes. AEGEA Medical aims to expand treatment options for a broader range of patients while ensuring convenience and confidence for physicians performing these office-based procedures. The company was incorporated in 2007 and continues to focus on enhancing patient outcomes in women's healthcare.

Cardeas Pharma is focused on developing an innovative antibiotic formulation that combines two drugs to target highly resistant Gram-negative bacilli, such as Pseudomonas aeruginosa and Acinetobacter baumannii, as well as carbapenem-resistant Enterobacteriaceae. This formulation is designed to treat serious respiratory infections in critical care settings, particularly those caused by antibiotic-resistant organisms. Additionally, it demonstrates efficacy against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), and has activity on biofilms. The delivery system utilizes a single-patient use, vibrating-plate nebulizer compatible with all ventilators, which generates small, uniform aerosol droplets that effectively reach the small airways and alveoli. By integrating this novel antibiotic formulation with advanced drug-delivery technology, Cardeas Pharma aims to achieve substantial clinical improvements over current treatment standards.

EBR Systems, Inc., established in 2003 and based in Sunnyvale, California, specializes in developing implantable systems for wireless tissue stimulation. The company focuses on treating cardiac arrhythmias by creating devices that improve heart function through wireless cardiac stimulation. Its flagship product is the Wise CRT System, which employs proprietary wireless technology to deliver pacing stimulation directly inside the left ventricle of the heart, enhancing its pumping efficiency and synchronizing rhythms.

EBR Systems, Inc., established in 2003 and based in Sunnyvale, California, specializes in developing implantable systems for wireless tissue stimulation. The company focuses on treating cardiac arrhythmias by creating devices that improve heart function through wireless cardiac stimulation. Its flagship product is the Wise CRT System, which employs proprietary wireless technology to deliver pacing stimulation directly inside the left ventricle of the heart, enhancing its pumping efficiency and synchronizing rhythms.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on innovative and long-term implantable glucose monitoring solutions that utilize advanced fluorescence sensing technology. Its flagship products, Eversense and Eversense XL, are implantable CGM systems designed to monitor glucose levels for up to 90 and 180 days, respectively. These products aim to provide users with a reliable and stable means of glucose management, enhancing their ability to live confidently and manage their diabetes effectively. The majority of Senseonics' revenue comes from international markets, reflecting its strong presence in Europe.

Sotera Wireless is a medical device company dedicated to developing, marketing, and selling a new generation of comprehensive vital signs monitoring. Its mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.

ForSight VISION5, founded in 2010 as part of ForSight Labs, specializes in the development of non-invasive drug delivery technologies aimed at treating major eye diseases such as glaucoma, dry eye, and allergies. The company is focused on creating innovative products that can replace traditional eye drops and offer sustained therapeutic effects. Currently, ForSight VISION5 is advancing its lead product, the Helios insert, which is undergoing its second Phase 2 clinical study, reflecting the company's commitment to improving patient care in ophthalmology through effective and patient-friendly solutions.

Sequent Medical is a privately-held medical device company focused on developing innovative catheter-based neurovascular technologies. Founded in 2006, the company is headquartered in Aliso Viejo, California, with additional operations in Bonn, Germany. Sequent Medical has invented and developed Microbraid technology to create the WEB Aneurysm Embolization System, a versatile treatment option for both ruptured and unruptured intracranial aneurysms. The WEB system has received CE mark approval and has been used to treat nearly 600 aneurysms in Europe, Latin America, and New Zealand. However, it is not available for sale or use in the United States.

Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company has created a minimally invasive intracanalicular scaffold that helps alleviate high intraocular pressure by restoring the natural drainage pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its glaucoma treatments, Ivantis plans to expand its research and development efforts to address other challenging diseases within the field of ophthalmology. The company's products are utilized in clinical trials by ophthalmology specialists across the United States.

TriVascular Technologies, Inc. is a medical device company focused on developing and commercializing innovative technologies for the minimally invasive treatment of abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA). Based in Santa Rosa, California, TriVascular specializes in endovascular grafts and self-expanding stent grafts, including the Ovation and Ovation Prime Stent Grafts, which utilize polymer-filled sealing rings to enhance procedural efficacy. The company’s products are designed to improve patient outcomes by reducing mortality, morbidity, and costs associated with traditional open surgical repair. TriVascular markets its technologies through direct sales in the United States and select European countries, as well as through distributors in other regions. Founded in 2007, TriVascular operates as a subsidiary of Endologix Inc. and emphasizes addressing unmet clinical needs while fostering a supportive work environment for its employees.

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule drugs targeting tumor metabolism and immunology for cancer treatment. Headquartered in South San Francisco, California, the company’s lead product candidate, CB-839, is an inhibitor of glutaminase currently in Phase II clinical trials for solid tumors. Additionally, Calithera is developing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology, as well as CB-280, another oral arginase inhibitor aimed at treating cystic fibrosis, and CB-708, an orally administered small molecule inhibitor of CD73. The company has established collaborations with Bristol-Myers Squibb to evaluate the combination of nivolumab with CB-839, and with Incyte Corporation for the development and commercialization of INCB001158. Founded in 2010, Calithera Biosciences is dedicated to advancing innovative therapies that specifically target critical pathways in tumor growth and survival.

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company based in Newton, Massachusetts, focused on the discovery and development of innovative drug therapies for cancer and other significant diseases. The company specializes in small molecule selective inhibitors of nuclear export (SINE) compounds, targeting the nuclear export protein exportin 1. Its lead product, XPOVIO, is approved in the U.S. for treating multiple myeloma in various settings. Karyopharm is advancing several clinical trials, including BOSTON and STORM for multiple myeloma, SADAL for diffuse large B-cell lymphoma, and SEAL for liposarcoma. Additionally, it is exploring the treatment of endometrial cancer through the SIENDO trial and glioblastoma multiforme in the KING trial. The company maintains collaborations to facilitate clinical trials and research efforts, including projects related to COVID-19. Karyopharm continues to develop various investigational programs aimed at expanding its therapeutic portfolio.

ForSight VISION5, founded in 2010 as part of ForSight Labs, specializes in the development of non-invasive drug delivery technologies aimed at treating major eye diseases such as glaucoma, dry eye, and allergies. The company is focused on creating innovative products that can replace traditional eye drops and offer sustained therapeutic effects. Currently, ForSight VISION5 is advancing its lead product, the Helios insert, which is undergoing its second Phase 2 clinical study, reflecting the company's commitment to improving patient care in ophthalmology through effective and patient-friendly solutions.

ForSight Labs is a company dedicated to developing innovative ophthalmic technologies aimed at improving the sight, care, and quality of life for visually impaired patients. With a focus on addressing the significant challenges posed by vision loss, including conditions like glaucoma, ForSight Labs collaborates with a team of motivated professionals, clinicians, and investors to bring new solutions to the ophthalmic community. The company recognizes the profound impact of vision impairment on individuals and society, as the number of people suffering from visual impairment is expected to increase significantly in the coming years. By driving the development and commercialization of high-impact eye care technologies, ForSight Labs aims to deliver effective treatments that enhance patient outcomes and address the substantial economic burden associated with vision loss.

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company based in Newton, Massachusetts, focused on the discovery and development of innovative drug therapies for cancer and other significant diseases. The company specializes in small molecule selective inhibitors of nuclear export (SINE) compounds, targeting the nuclear export protein exportin 1. Its lead product, XPOVIO, is approved in the U.S. for treating multiple myeloma in various settings. Karyopharm is advancing several clinical trials, including BOSTON and STORM for multiple myeloma, SADAL for diffuse large B-cell lymphoma, and SEAL for liposarcoma. Additionally, it is exploring the treatment of endometrial cancer through the SIENDO trial and glioblastoma multiforme in the KING trial. The company maintains collaborations to facilitate clinical trials and research efforts, including projects related to COVID-19. Karyopharm continues to develop various investigational programs aimed at expanding its therapeutic portfolio.

Revance Therapeutics is a biopharmaceutical company focused on developing and commercializing products for dermatology and aesthetics. Its lead product, RT001, is a topical botulinum toxin type A for cosmetic use, hyperhidrosis treatment, and other dermatological indications.

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.

Sotera Wireless is a medical device company dedicated to developing, marketing, and selling a new generation of comprehensive vital signs monitoring. Its mission is to improve patient safety by empowering clinicians to detect early signs of deterioration in virtually any care setting and enable early intervention and rapid response, all without limiting the patient’s freedom of movement.

Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company has created a minimally invasive intracanalicular scaffold that helps alleviate high intraocular pressure by restoring the natural drainage pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its glaucoma treatments, Ivantis plans to expand its research and development efforts to address other challenging diseases within the field of ophthalmology. The company's products are utilized in clinical trials by ophthalmology specialists across the United States.

Labcyte Inc., founded in 2000 and based in San Jose, California, specializes in developing acoustic droplet ejection (ADE) technology for various applications in the life sciences. The company's innovative approach uses focused beams of acoustic energy to precisely dispense nanoliter-scale droplets of fluid from one plate to another, enabling high accuracy at low volumes and reducing consumables costs. Labcyte's products include automation systems, laboratory workstations, and control software, which are utilized in drug discovery, genomics research, cancer research, and personalized medicine. The company operates as a subsidiary of Beckman Coulter, Inc., with additional offices across multiple countries including Canada, the United Kingdom, Australia, India, South Korea, China, Hong Kong, Japan, Singapore, and Taiwan.

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule drugs targeting tumor metabolism and immunology for cancer treatment. Headquartered in South San Francisco, California, the company’s lead product candidate, CB-839, is an inhibitor of glutaminase currently in Phase II clinical trials for solid tumors. Additionally, Calithera is developing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology, as well as CB-280, another oral arginase inhibitor aimed at treating cystic fibrosis, and CB-708, an orally administered small molecule inhibitor of CD73. The company has established collaborations with Bristol-Myers Squibb to evaluate the combination of nivolumab with CB-839, and with Incyte Corporation for the development and commercialization of INCB001158. Founded in 2010, Calithera Biosciences is dedicated to advancing innovative therapies that specifically target critical pathways in tumor growth and survival.

Tandem Diabetes Care is a medical device company that designs, manufactures, and markets insulin pumps and related diabetes management solutions. Founded in 2006 and headquartered in San Diego, the company’s flagship product is the t:slim X2 insulin delivery system, which includes a compact pump, a 300‑unit disposable cartridge, and an infusion set. The system is available with Basal‑IQ, Control‑IQ, and G5 integration features, and can be updated through the Tandem Device Updater. Tandem also offers the t:connect web application for data visualization and the Sugarmate mobile app for insulin‑using patients. In development are the t:sport pump, the Mobi and Tobi tubeless pumps, and the Sigi patch pump. The company partners with Dexcom for integrated glucose monitoring and sells its products primarily in the United States, with a growing presence in other developed markets.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, focused on the development and commercialization of innovative medicines for iron deficiency, nephrology, and cardio-renal conditions. Incorporated in 2007, Relypsa specializes in non-absorbed polymeric drugs, aiming to address medical needs in these therapeutic areas. Its flagship product, VELTASSA, is a potassium binder used in the treatment of hyperkalemia, a condition characterized by elevated potassium levels in the blood. The company targets overlooked and undertreated conditions that can be managed through gastrointestinal applications. As of late 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, focused on the development and commercialization of innovative medicines for iron deficiency, nephrology, and cardio-renal conditions. Incorporated in 2007, Relypsa specializes in non-absorbed polymeric drugs, aiming to address medical needs in these therapeutic areas. Its flagship product, VELTASSA, is a potassium binder used in the treatment of hyperkalemia, a condition characterized by elevated potassium levels in the blood. The company targets overlooked and undertreated conditions that can be managed through gastrointestinal applications. As of late 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

Astute Medical, Inc. is a life science tools company focused on improving the diagnosis of high-risk medical conditions through the discovery and development of protein biomarkers. Founded in 2007 and based in San Diego, California, with an additional location in Paris, France, the company specializes in creating novel diagnostic tests that enable rapid diagnosis and risk assessment for conditions such as abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. Astute Medical's flagship product, NephroCheck, is a single-use cartridge designed to detect biomarkers associated with acute kidney injury, while the Astute140 meter converts the test's fluorescent signal into a single numerical result. The company markets its products primarily in the United States and Europe and operates as a subsidiary of bioMérieux S.A.

TriVascular Technologies, Inc. is a medical device company focused on developing and commercializing innovative technologies for the minimally invasive treatment of abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA). Based in Santa Rosa, California, TriVascular specializes in endovascular grafts and self-expanding stent grafts, including the Ovation and Ovation Prime Stent Grafts, which utilize polymer-filled sealing rings to enhance procedural efficacy. The company’s products are designed to improve patient outcomes by reducing mortality, morbidity, and costs associated with traditional open surgical repair. TriVascular markets its technologies through direct sales in the United States and select European countries, as well as through distributors in other regions. Founded in 2007, TriVascular operates as a subsidiary of Endologix Inc. and emphasizes addressing unmet clinical needs while fostering a supportive work environment for its employees.

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Bothell, Washington, focused on discovering, developing, and commercializing therapeutic antibodies. The company aims to transform treatment paradigms for patients with migraine and other conditions, utilizing proprietary technologies to enhance the efficacy and durability of therapeutic responses. Its lead product candidate, eptinezumab, is a monoclonal antibody designed to prevent migraines, currently in late-stage clinical development. Additionally, Alder is developing ALD1910, a preclinical monoclonal antibody for migraine prevention, and Clazakizumab, which targets interleukin-6 and has completed two Phase 2b clinical trials. Alder also collaborates with CSL Limited to develop Clazakizumab for preventing solid organ transplant rejection. The company operates primarily in the United States, Australia, and Ireland, where it seeks to address unmet medical needs in various therapeutic areas, including cancer, autoimmune diseases, and inflammatory disorders. Founded in 2002, Alder BioPharmaceuticals operates as a subsidiary of H. Lundbeck A/S.

Sequent Medical is a privately-held medical device company focused on developing innovative catheter-based neurovascular technologies. Founded in 2006, the company is headquartered in Aliso Viejo, California, with additional operations in Bonn, Germany. Sequent Medical has invented and developed Microbraid technology to create the WEB Aneurysm Embolization System, a versatile treatment option for both ruptured and unruptured intracranial aneurysms. The WEB system has received CE mark approval and has been used to treat nearly 600 aneurysms in Europe, Latin America, and New Zealand. However, it is not available for sale or use in the United States.

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule drugs targeting tumor metabolism and immunology for cancer treatment. Headquartered in South San Francisco, California, the company’s lead product candidate, CB-839, is an inhibitor of glutaminase currently in Phase II clinical trials for solid tumors. Additionally, Calithera is developing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology, as well as CB-280, another oral arginase inhibitor aimed at treating cystic fibrosis, and CB-708, an orally administered small molecule inhibitor of CD73. The company has established collaborations with Bristol-Myers Squibb to evaluate the combination of nivolumab with CB-839, and with Incyte Corporation for the development and commercialization of INCB001158. Founded in 2010, Calithera Biosciences is dedicated to advancing innovative therapies that specifically target critical pathways in tumor growth and survival.

Pivot Medical is a privately held medical device company specializing in the development and marketing of innovative technologies within the orthopedic sector. The company focuses on creating minimally invasive hip-restoration systems aimed at enhancing surgical access and reducing recovery times for patients. Its product offerings include hip-replacement devices and arthroscopic surgery techniques, catering to individuals seeking effective and less invasive treatment options for orthopedic conditions. With a commitment to advancing medical solutions, Pivot Medical addresses the needs of active individuals looking for efficient and effective healthcare alternatives.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, focused on the development and commercialization of innovative medicines for iron deficiency, nephrology, and cardio-renal conditions. Incorporated in 2007, Relypsa specializes in non-absorbed polymeric drugs, aiming to address medical needs in these therapeutic areas. Its flagship product, VELTASSA, is a potassium binder used in the treatment of hyperkalemia, a condition characterized by elevated potassium levels in the blood. The company targets overlooked and undertreated conditions that can be managed through gastrointestinal applications. As of late 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

PolyRemedy offers integrated wound management systems designed to increase consistency by extending wound care expertise to the point of care. The PolyRemedy Personalized Woundcare System (PWS) enables clinicians to document care through easy-to-use, web-based assessment tools and order personalized wound dressings, while also providing critical and unprecedented visibility into wound care data. It was founded in 2004 and is headquartered in Concord, Massachusetts.

AEGEA Medical, Inc. is a medical technology company based in Menlo Park, California, that specializes in innovative treatments for women's health. The company has developed a water vapor ablation system, known as Mara, which is designed for the in-office treatment of heavy menstrual bleeding, specifically menorrhagia. This FDA-approved technology utilizes adaptive vapor ablation to deliver safe and effective endometrial ablation in a simple procedure that takes only minutes. AEGEA Medical aims to expand treatment options for a broader range of patients while ensuring convenience and confidence for physicians performing these office-based procedures. The company was incorporated in 2007 and continues to focus on enhancing patient outcomes in women's healthcare.

Cameron Health, Inc. is a development stage medical device company focused on creating innovative implantable electronic devices. With a team of experienced professionals, the company specializes in the development and manufacturing of subcutaneous implantable defibrillator (S-ICD) systems, designed for patients at risk of ventricular tachyarrhythmias. The S-ICD system includes key components such as the SQ-RX pulse generator, which delivers electrical pulses to manage cardiac arrhythmias, and the Q-TRAK subcutaneous electrode, implanted parallel to the left sternal border. Additionally, the Q-TECH programmer wirelessly communicates with the SQ-RX device, enhancing patient management. Cameron Health aims to provide advanced treatment options that were previously unattainable, leveraging state-of-the-art technologies to address complex medical challenges.

PixelOptics was founded in 2005 as the world's first composite lens company. Their unique and proprietary approach to lens design combines sound lens design principles and well-known, proven lens materials to create entirely new categories of eyeglass lenses.

Astute Medical, Inc. is a life science tools company focused on improving the diagnosis of high-risk medical conditions through the discovery and development of protein biomarkers. Founded in 2007 and based in San Diego, California, with an additional location in Paris, France, the company specializes in creating novel diagnostic tests that enable rapid diagnosis and risk assessment for conditions such as abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. Astute Medical's flagship product, NephroCheck, is a single-use cartridge designed to detect biomarkers associated with acute kidney injury, while the Astute140 meter converts the test's fluorescent signal into a single numerical result. The company markets its products primarily in the United States and Europe and operates as a subsidiary of bioMérieux S.A.

EBR Systems, Inc., established in 2003 and based in Sunnyvale, California, specializes in developing implantable systems for wireless tissue stimulation. The company focuses on treating cardiac arrhythmias by creating devices that improve heart function through wireless cardiac stimulation. Its flagship product is the Wise CRT System, which employs proprietary wireless technology to deliver pacing stimulation directly inside the left ventricle of the heart, enhancing its pumping efficiency and synchronizing rhythms.

ELENZA, Inc. is a medical technology company specializing in the development and commercialization of innovative electro-active AutoFocal intraocular lenses (IOLs) designed to enhance vision for patients undergoing cataract extraction and to address presbyopia. Founded in 2008 and based in Roanoke, Virginia, with an additional office in Zürich, Switzerland, ELENZA's proprietary IOL technology utilizes a unique combination of liquid-crystal chemistry, electricity, and integrated circuitry to create smart optics. These lenses automatically adjust their focusing power electronically, allowing for seamless transitions between near, intermediate, and distance vision. The electro-active lenses are powered by a micro-sized battery with a long rechargeable cycle life, aiming to provide a natural and clear visual experience across various lighting conditions.

NeurAxon, Inc. is a Canadian company focused on discovering and developing therapeutics for pain management by targeting neuronal nitric oxide synthase. Founded in 2004 and headquartered in Toronto, NeurAxon is advancing a pipeline of oral products aimed at treating various pain conditions, including acute migraine, neuropathic pain, chronic daily headache, inflammatory pain, migraine prophylaxis, and severe pain. By utilizing selective inhibitors of nitric oxide synthase, the company seeks to provide effective solutions for individuals suffering from these conditions.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, focused on the development and commercialization of innovative medicines for iron deficiency, nephrology, and cardio-renal conditions. Incorporated in 2007, Relypsa specializes in non-absorbed polymeric drugs, aiming to address medical needs in these therapeutic areas. Its flagship product, VELTASSA, is a potassium binder used in the treatment of hyperkalemia, a condition characterized by elevated potassium levels in the blood. The company targets overlooked and undertreated conditions that can be managed through gastrointestinal applications. As of late 2016, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

NeuroVista Corporation is a medical device company based in Seattle, Washington, focused on developing innovative technologies for the management and treatment of epilepsy in the United States. Founded in 2002 and originally known as BioNeuronics Corporation until its rebranding in 2007, NeuroVista aims to address the challenges faced by the approximately 3 million Americans living with epilepsy, a neurological condition characterized by unpredictable seizures. These seizures can vary significantly in severity and impact daily life, affecting individuals primarily between the ages of 15 and 64. Through its advisory technologies, NeuroVista seeks to provide tools that help mitigate the uncertainty surrounding the timing of epileptic seizures, ultimately improving the quality of life for those affected by this condition.

TriVascular Technologies, Inc. is a medical device company focused on developing and commercializing innovative technologies for the minimally invasive treatment of abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA). Based in Santa Rosa, California, TriVascular specializes in endovascular grafts and self-expanding stent grafts, including the Ovation and Ovation Prime Stent Grafts, which utilize polymer-filled sealing rings to enhance procedural efficacy. The company’s products are designed to improve patient outcomes by reducing mortality, morbidity, and costs associated with traditional open surgical repair. TriVascular markets its technologies through direct sales in the United States and select European countries, as well as through distributors in other regions. Founded in 2007, TriVascular operates as a subsidiary of Endologix Inc. and emphasizes addressing unmet clinical needs while fostering a supportive work environment for its employees.

BARRX Medical specializes in developing endoscopic treatment solutions for Barrett's esophagus, a precancerous condition of the esophagus. Its HALO systems use radiofrequency ablation to remove diseased tissue and allow normal cell regrowth. With over 58,000 procedures performed worldwide, BARRX Medical aims to provide effective, non-surgical treatments for patients.

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule drugs targeting tumor metabolism and immunology for cancer treatment. Headquartered in South San Francisco, California, the company’s lead product candidate, CB-839, is an inhibitor of glutaminase currently in Phase II clinical trials for solid tumors. Additionally, Calithera is developing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology, as well as CB-280, another oral arginase inhibitor aimed at treating cystic fibrosis, and CB-708, an orally administered small molecule inhibitor of CD73. The company has established collaborations with Bristol-Myers Squibb to evaluate the combination of nivolumab with CB-839, and with Incyte Corporation for the development and commercialization of INCB001158. Founded in 2010, Calithera Biosciences is dedicated to advancing innovative therapies that specifically target critical pathways in tumor growth and survival.

Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy).

Founded in 2005, Breathe Technologies develops innovative respiratory therapies aimed at improving patients' mobility and quality of life. The company specializes in lightweight, portable ventilator systems designed for use in hospitals and homes, targeting conditions such as interstitial lung diseases, neuromuscular disorders, and post-transplant care.

Astute Medical, Inc. is a life science tools company focused on improving the diagnosis of high-risk medical conditions through the discovery and development of protein biomarkers. Founded in 2007 and based in San Diego, California, with an additional location in Paris, France, the company specializes in creating novel diagnostic tests that enable rapid diagnosis and risk assessment for conditions such as abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. Astute Medical's flagship product, NephroCheck, is a single-use cartridge designed to detect biomarkers associated with acute kidney injury, while the Astute140 meter converts the test's fluorescent signal into a single numerical result. The company markets its products primarily in the United States and Europe and operates as a subsidiary of bioMérieux S.A.

Tandem Diabetes Care is a medical device company that designs, manufactures, and markets insulin pumps and related diabetes management solutions. Founded in 2006 and headquartered in San Diego, the company’s flagship product is the t:slim X2 insulin delivery system, which includes a compact pump, a 300‑unit disposable cartridge, and an infusion set. The system is available with Basal‑IQ, Control‑IQ, and G5 integration features, and can be updated through the Tandem Device Updater. Tandem also offers the t:connect web application for data visualization and the Sugarmate mobile app for insulin‑using patients. In development are the t:sport pump, the Mobi and Tobi tubeless pumps, and the Sigi patch pump. The company partners with Dexcom for integrated glucose monitoring and sells its products primarily in the United States, with a growing presence in other developed markets.

EBR Systems, Inc., established in 2003 and based in Sunnyvale, California, specializes in developing implantable systems for wireless tissue stimulation. The company focuses on treating cardiac arrhythmias by creating devices that improve heart function through wireless cardiac stimulation. Its flagship product is the Wise CRT System, which employs proprietary wireless technology to deliver pacing stimulation directly inside the left ventricle of the heart, enhancing its pumping efficiency and synchronizing rhythms.

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.

TriVascular Technologies, Inc. is a medical device company focused on developing and commercializing innovative technologies for the minimally invasive treatment of abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA). Based in Santa Rosa, California, TriVascular specializes in endovascular grafts and self-expanding stent grafts, including the Ovation and Ovation Prime Stent Grafts, which utilize polymer-filled sealing rings to enhance procedural efficacy. The company’s products are designed to improve patient outcomes by reducing mortality, morbidity, and costs associated with traditional open surgical repair. TriVascular markets its technologies through direct sales in the United States and select European countries, as well as through distributors in other regions. Founded in 2007, TriVascular operates as a subsidiary of Endologix Inc. and emphasizes addressing unmet clinical needs while fostering a supportive work environment for its employees.

BaroSense is focused on developing and commercializing innovative medical devices aimed at addressing obesity, a significant healthcare challenge in the United States. The company aims to provide safe, simple, and effective alternatives to surgical treatments for obesity, catering to individuals who require assistance beyond traditional dieting methods and wish to avoid extensive and irreversible surgical options. BaroSense's product offerings include minimally invasive therapeutic procedures and devices, such as a trans-oral endoscopic restrictive implant system, designed to facilitate weight loss in a less invasive manner.

VytronUS, Inc. is a manufacturer of cardiac medical devices, specializing in solutions for treating cardiac arrhythmia. Founded in 2006 and based in Sunnyvale, California, the company develops innovative technologies that leverage ultrasound energy for both imaging and therapeutic purposes. Its devices facilitate precise, non-contact energy delivery and create high-resolution maps of cardiac anatomy, empowering physicians to address complex arrhythmias with enhanced visualization and precision. VytronUS's focus on automation and flexibility in its device offerings positions it as a key player in the cardiac medical device market.

Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy).